Toxoplasmosis Treatment Drugs Market, by Indication (Chronic Toxoplasmosis Infection, and Acute Toxoplasmosis Infection), by Route of Administration (Parenteral, and Oral), by Drug Class (Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, an

Toxoplasmosis Treatment Drugs Market, by Indication (Chronic Toxoplasmosis Infection, and Acute Toxoplasmosis Infection), by Route of Administration (Parenteral, and Oral), by Drug Class (Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, and Others), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Toxoplasma gondii is an intracellular parasite, which can cause lifelong infection. The infection lives in the brain and sometimes in the eyes in about 30 percent of all humans. It is caused due to drinking contaminated water, consuming infected undercooked meat, or exposure to these parasites in soil. These parasites usually occur in unborn babies, newborns, children and adults. While most healthy adults who are exposed to the parasite never experience any serious symptoms, but dormant, unrecognized, smoldering infections can emerge years later in immune-compromised patients.
Market Dynamics
Increasing incidence of cancer is expected to increase the chemotherapy procedures leading to the toxoplasmosis infection, and thereby driving the market growth over the forecast period. According to the World Cancer Research Fund International’s report, in 2018 lung cancer was at first position in the total number of cancer cases worldwide, accounting for 2,093,876 new cases worldwide in 2018. According to the same source, breast cancer accounted second position and the new cases reported was 2,088,849 globally in 2018.
Rising number of chemotherapy procedures can lead to increase in the number of toxoplasmosis infection thereby assisting the market growth. According to the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, in November 2020, stated that nearly 650,000 cancer patients in the U.S. receive chemotherapy in an outpatient oncology clinic annually.
Increasing prevalence of Acquired Immunodeficiency Syndrome (AIDS) caused due to HIV may lead to low immunity and toxoplasmosis infection and, thereby, drive the growth of toxoplasmosis treatment drugs market during the forecast period. For instance, according to the UNAIDS, 2021, around 1.7 million new cases of HIV infection was registered globally in 2018.
Key features of the study:
This report provides in-depth analysis of the global toxoplasmosis treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global toxoplasmosis treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global toxoplasmosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global toxoplasmosis treatment drugs market.
Detailed Segmentation:
Global Toxoplasmosis Treatment Drugs Market, By Indication:
Chronic Toxoplasmosis Infection
Acute Toxoplasmosis Infection
Global Toxoplasmosis Treatment Drugs Market, By Route of Administration:
Parenteral
Oral
Global Toxoplasmosis Treatment Drugs Market, By Drug Class:
Pyrimethamine
Spiramycin
Leucovorin
Sulfadiazine
Folic Acid
Other
Global Toxoplasmosis Treatment Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Toxoplasmosis Treatment Drugs Market, By Region:
North America
By Indication:
Chronic Toxoplasmosis Infection
Acute Toxoplasmosis Infection
By Route of Administration
Parenteral
Oral
By Drug Class
Pyrimethamine
Spiramycin
Leucovorin
Sulfadiazine
Folic Acid
Other
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Indication:
Chronic Toxoplasmosis Infection
Acute Toxoplasmosis Infection
By Route of Administration
Parenteral
Oral
By Drug Class
Pyrimethamine
Spiramycin
Leucovorin
Sulfadiazine
Folic Acid
Other
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Indication:
Chronic Toxoplasmosis Infection
Acute Toxoplasmosis Infection
By Route of Administration
Parenteral
Oral
By Drug Class
Pyrimethamine
Spiramycin
Leucovorin
Sulfadiazine
Folic Acid
Other
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Indication:
Chronic Toxoplasmosis Infection
Acute Toxoplasmosis Infection
By Route of Administration
Parenteral
Oral
By Drug Class
Pyrimethamine
Spiramycin
Leucovorin
Sulfadiazine
Folic Acid
Other
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Indication:
Chronic Toxoplasmosis Infection
Acute Toxoplasmosis Infection
By Route of Administration
Parenteral
Oral
By Drug Class
Pyrimethamine
Spiramycin
Leucovorin
Sulfadiazine
Folic Acid
Other
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Indication:
Chronic Toxoplasmosis Infection
Acute Toxoplasmosis Infection
By Route of Administration
Parenteral
Oral
By Drug Class
Pyrimethamine
Spiramycin
Leucovorin
Sulfadiazine
Folic Acid
Other
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Vyera Pharmaceuticals LLC*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Taj Accura Pharmaceuticals Ltd
Mangalam Drugs and Organics Ltd.
Cerovene Healthcare PVT LTD
Greenstone LLC
Amneal Pharmaceuticals, Inc.
Turing Pharmaceuticals
F. Hoffmann-La Roche AG
Teva Pharmaceutical Industries Ltd
Baxter International Inc.
“*” marked represents similar segmentation in other categories in the respective section.